Betaine

Major Depressive Disorder

Cambridge Health AllianceSmall moleculePhase 4 / ApprovedDormant

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 95/ 100

Competitive context

198 Active assets in the Major Depressive Disorder cohort.

Asset / Sponsor	Phase	Rating
Risperidone Johns Hopkins University	Phase 4	BBB
Selegiline Corium Innovations, Inc.	Phase 4	BBB
Edivoxetine Eli Lilly and Company	Phase 3	BBB
(1S,2R)-MILNACIPRAN Allergan	Phase 4	BBB
Brexpiprazole Nova Scotia Health Authority	Phase 4	BBB

View all 50 →

Same molecule, other indications

Betaine is also rated in:

peroxisome biogenesis disorderDormant

BB

Indicative · Phase 3

64 / 100

metabolic dysfunction-associated steatohepatitisActive

B

Indicative · Phase 2

57 / 100

obesity disorderDormant

CCC

Indicative · Phase 2

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.